Evidence map›Paper›PMID 37426639›Full record

ReviewFrontiers in immunology2023

A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab.

Rongmao Gao, Fuxun Yang, Chen Yang, Zhao Zhang, Mingzong Liu, Chunlin Xiang, Huan Hu, Xiaoxiu Luo, Jiajia Li, Rongan Liu

Open access · goldAbstract readReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Rongmao GaoDepartment of Intensive Care Unit (ICU), Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Fuxun YangDepartment of Intensive Care Unit (ICU), Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Chen YangDepartment of Intensive Care Unit (ICU), Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Zhao ZhangDepartment of Intensive Care Unit (ICU), Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Mingzong LiuDepartment of Intensive Care Unit (ICU), Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Chunlin XiangDepartment of Intensive Care Unit (ICU), Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Huan HuDepartment of Intensive Care Unit (ICU), Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Xiaoxiu LuoDepartment of Intensive Care Unit (ICU), Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Jiajia LiDepartment of Intensive Care Unit (ICU), Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Rongan LiuDepartment of Intensive Care Unit (ICU), Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
University of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: From the perspective of intensive care physicians, this paper reviews the diagnosis and treatment of CIP patients, analyzes and refines relevant literature on CIP. To summarize the characteristics of diagnosis and treatment of severe CIP provides the basis and reference for early identification, diagnosis and treatment. Methods: A case of severe CIP caused by piamprilizumab and ICI was reviewed and the literature was reviewed. Results: This was a patient with lung squamous cell carcinoma with lymphoma who had been treated with multiple chemoradiotherapy and immunotherapy with piamprizumab. The patient was admitted to the ICU with respiratory failure. The intensive care physician performs anti-infective, fluid management, hormonal anti-inflammatory, respiratory and nutritional support treatment, and relies on mNGS to exclude severe infection and CIP treatment, thus successfully saving the patient's life and improving discharge. Conclusions: The incidence of CIP is very low, and its diagnosis should be combined with clinical manifestations and previous drug use. mNGS can provide certain value in the exclusion of severe infections, so as to provide basis and reference for the early identification, diagnosis and treatment of severe CIP.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsPneumoniaAntibodies, Monoclonal, HumanizedHumansImmune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitorspenpulimabcheckpoint inhibitor pneumonitisICUimmune checkpoint inhibitormetagenomic next-generation sequencingsevere infection

Identifiers

PMID37426639
PMCPMC10323425
OpenAlexW4381687246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.